Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Quetiapine: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Josikins
Created page with "Quetiapine (/kwɨˈtaɪ.əpiːn/ kwi-ty-ə-peen) (branded as '''Seroquel''', '''Xeroquel''', '''Ketipinor''') is a short-acting atypical antipsychotic approved for the tre..."
 
>Josikins
No edit summary
Line 2: Line 2:


Annual sales are approximately $5.7 billion worldwide, with $2.9 billion in the United States.<ref>http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=SEROQUEL</ref> The U.S. patent,<ref>http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288</ref> which was set to expire in 2011, received a pediatric exclusivity extension which pushed its expiration to March 26, 2012.<ref>http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288</ref><ref>Blockbuster Drugs That Will Go Generic Soon | http://money.usnews.com/money/blogs/the-best-life/2011/04/29/blockbuster-drugs-that-will-go-generic-soon</ref> The patent has already expired in Canada. Quetiapine was developed by AstraZeneca from 1992-1996 as an improvement from first generation antipsychotics. It was first approved by the FDA in 1997. There are now several generic versions of quetiapine, such as Quepin, Syquel and Ketipinor.<ref>http://www.theodora.com/drugs/quepin_tablets_specifar.html</ref>
Annual sales are approximately $5.7 billion worldwide, with $2.9 billion in the United States.<ref>http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=SEROQUEL</ref> The U.S. patent,<ref>http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288</ref> which was set to expire in 2011, received a pediatric exclusivity extension which pushed its expiration to March 26, 2012.<ref>http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=4,879,288.PN.&OS=PN/4,879,288&RS=PN/4,879,288</ref><ref>Blockbuster Drugs That Will Go Generic Soon | http://money.usnews.com/money/blogs/the-best-life/2011/04/29/blockbuster-drugs-that-will-go-generic-soon</ref> The patent has already expired in Canada. Quetiapine was developed by AstraZeneca from 1992-1996 as an improvement from first generation antipsychotics. It was first approved by the FDA in 1997. There are now several generic versions of quetiapine, such as Quepin, Syquel and Ketipinor.<ref>http://www.theodora.com/drugs/quepin_tablets_specifar.html</ref>
==Chemistry==
==Pharmocology==
==Subjective effects==
===Physical effects===
===Cognitive effects===
==Toxicity and harm potential==
===Tolerance and addiction potential===
===Interactions===
==Legal issues==
==References==
<references/>

Revision as of 14:18, 30 April 2014

Quetiapine (/kwɨˈtaɪ.əpiːn/ kwi-ty-ə-peen) (branded as Seroquel, Xeroquel, Ketipinor) is a short-acting atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and along with an antidepressant to treat major depressive disorder.

Annual sales are approximately $5.7 billion worldwide, with $2.9 billion in the United States.[1] The U.S. patent,[2] which was set to expire in 2011, received a pediatric exclusivity extension which pushed its expiration to March 26, 2012.[3][4] The patent has already expired in Canada. Quetiapine was developed by AstraZeneca from 1992-1996 as an improvement from first generation antipsychotics. It was first approved by the FDA in 1997. There are now several generic versions of quetiapine, such as Quepin, Syquel and Ketipinor.[5]

Chemistry

Pharmocology

Subjective effects

Physical effects

Cognitive effects

Toxicity and harm potential

Tolerance and addiction potential

Interactions

References